Raymond James Sticks to Its Buy Rating for Johnson & Johnson (JNJ)

By Ryan Adsit

Raymond James analyst Jayson Bedford maintained a Buy rating on Johnson & Johnson (JNJResearch Report) today and set a price target of $145.00. The company’s shares closed last Monday at $131.33.

According to TipRanks.com, Bedford is a top 100 analyst with an average return of 15.1% and a 68.6% success rate. Bedford covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Merit Medical Systems, and Edwards Lifesciences.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Johnson & Johnson with a $151.20 average price target, representing a 15.1% upside. In a report issued on October 2, Credit Suisse also reiterated a Buy rating on the stock with a $156.00 price target.

See today’s analyst top recommended stocks >>

Johnson & Johnson’s market cap is currently $346.6B and has a P/E ratio of 21.77. The company has a Price to Book ratio of 5.71.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.